EMEA-000174-PIP01-07-M03

Key facts

Invented name
Mozobil
Active substance
Plerixafor
Therapeutic area
Oncology
Decision number
P/0253/2013
PIP number
EMEA-000174-PIP01-07-M03
Pharmaceutical form(s)
Solution for injection
Condition(s) / indication(s)
Myelosuppression caused by chemotherapy to treat malignant disorders, which requires an autologous haematopoietic stem cell transplant
Route(s) of administration
  • Subcutaneous use
  • Intravenous use
Contact for public enquiries
Genzyme Europe B.V.

E-mail: eumedinfo@genzyme.com
Tel. +31 3569 98685

Decision type
PM: decision on the application for modification of an agreed PIP
Compliance procedure number
EMEA-C-000174-PIP01-07-M03
Compliance opinion date
26/01/2018
Compliance outcome
positive

Decision

How useful was this page?

Add your rating